Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLPHIN Moms
NCT05122026Phase 2Active, not recruiting
- Sponsor
- Aurum Institute
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifapentine and isoniazid in Tuberculosis (TB) (2 arms), sponsored by Aurum Institute. Primary endpoints: Mortality, Targeted Serious Adverse Events and 3 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05122026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122026.